[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 33 of about 33
1. Cantu de Leon D, Perez Montiel D, Tabarez A, Martinez RM, Cetina L: Serous adenocarcinoma of the fallopian tube, associated with verrucous carcinoma of the uterine cervix: a case report of synchronic rare gynecological tumors. World J Surg Oncol; 2009;7:20
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serous adenocarcinoma of the fallopian tube, associated with verrucous carcinoma of the uterine cervix: a case report of synchronic rare gynecological tumors.
  • BACKGROUND: Synchronous gynecological tumors are rare; it is even rarer to find the rarest of gynecological tumors that of the fallopian tube, together with a histological sub-type as rare as verrucous cervix.
  • CASE PRESENTATION: We report a synchronic fallopian tube adenocarcinoma and a verrucous cervical cancer.
  • A 85-year-old woman with postmenopausal genital hemorrhage, endometrial biopsy was reported as squamous metaplasia, an exploratory laparotomy was performed finding a tubal tumor diagnosed as adenocarcinoma, a staging procedure was performed.
  • Final staging revealed IB1 cervical carcinoma and IA G3 fallopian tube carcinoma.
  • Adjuvant treatment with chemotherapy was not accepted by the patient.
  • CONCLUSION: Reasons for our presentation of this work are: first, due to the rarity of these, and second, because of the usefulness of possessing a case report for establishing a norm for later behavior with respect to treatment of these patients.
  • [MeSH-major] Carcinoma, Verrucous / pathology. Cystadenocarcinoma, Serous / pathology. Fallopian Tube Neoplasms / pathology. Neoplasms, Multiple Primary / diagnosis. Uterine Cervical Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] BJOG. 2007 Apr;114(4):425-9 [17309544.001]
  • [Cites] Eur J Gynaecol Oncol. 2007;28(6):501-2 [18179146.001]
  • [Cites] Int J Gynecol Cancer. 2006 Jan-Feb;16(1):29-35 [16445606.001]
  • [Cites] Zhonghua Yi Xue Za Zhi (Taipei). 2000 Oct;63(10):765-9 [11076434.001]
  • [Cites] Pathol Res Pract. 1998;194(10):713-20 [9820868.001]
  • [Cites] Nucleic Acids Res. 1997 Sep 1;25(17):3389-402 [9254694.001]
  • [Cites] Ugeskr Laeger. 1993 Feb 22;155(8):565-6 [8451794.001]
  • [Cites] Nihon Sanka Fujinka Gakkai Zasshi. 1984 Apr;36(4):617-22 [6715942.001]
  • [Cites] Acta Cytol. 2003 Nov-Dec;47(6):1050-4 [14674078.001]
  • [Cites] Eur J Gynaecol Oncol. 2003;24(1):73-5 [12691323.001]
  • [Cites] J Obstet Gynaecol Res. 2000 Jun;26(3):189-92 [10932980.001]
  • [Cites] Oncologist. 2006 Sep;11(8):902-12 [16951394.001]
  • [Cites] Arch Gynecol Obstet. 2008 Jun;277(6):557-62 [18066567.001]
  • [Cites] Anticancer Res. 2007 Nov-Dec;27(6C):4491-4 [18214065.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 2008 Jan;136(1):78-82 [17049712.001]
  • (PMID = 19222847.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2649116
  •  go-up   go-down


2. Tahri A, Jouhadi H, Fadil H, Benchekroun N, Khalid H, Rafai A, Sahraoui S, Acharki A, Benider A, Slassi I, Kahlain A: [Association of fallopian tube cancer and polymyositis. Apropos of 1 case]. J Gynecol Obstet Biol Reprod (Paris); 2001 Oct;30(6):601-3
Genetic Alliance. consumer health - Polymyositis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Association of fallopian tube cancer and polymyositis. Apropos of 1 case].
  • Pathology examination of the right annexectomy specimen provided the definitive diagnosis: fallopian tube cancer with polymyositis.
  • The patient was lost to follow-up for three years without complementary treatment then consulted later for functional disability of the upper then lower limbs with myalgia, swallowing disorders and left supraclavian node enlargement resulting from pelvic relapse of the right fallopian tube adenocarcinoma and left supraclavian metastasis with paraneoplastic polymositis.
  • The patient was given 6 courses of chemotherapy with radiotherapy (45 Gy) centered on the left clavian region.
  • The association of a fallopian tube tumor with polymyositis is exceptional, requiring rapid anticancer treatment effective against the cancer and the paraneoplastic polymyositis.
  • [MeSH-major] Adenocarcinoma / complications. Fallopian Tube Neoplasms / complications. Polymyositis / complications
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Female. Humans. Hysterectomy. Middle Aged. Neoplasm Recurrence, Local. Radiotherapy. Remission Induction

  • Genetic Alliance. consumer health - Fallopian Tube Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11883028.001).
  • [ISSN] 0368-2315
  • [Journal-full-title] Journal de gynécologie, obstétrique et biologie de la reproduction
  • [ISO-abbreviation] J Gynecol Obstet Biol Reprod (Paris)
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


3. Tiersten AD, Liu PY, Smith HO, Wilczynski SP, Robinson WR 3rd, Markman M, Alberts DS: Phase II evaluation of neoadjuvant chemotherapy and debulking followed by intraperitoneal chemotherapy in women with stage III and IV epithelial ovarian, fallopian tube or primary peritoneal cancer: Southwest Oncology Group Study S0009. Gynecol Oncol; 2009 Mar;112(3):444-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II evaluation of neoadjuvant chemotherapy and debulking followed by intraperitoneal chemotherapy in women with stage III and IV epithelial ovarian, fallopian tube or primary peritoneal cancer: Southwest Oncology Group Study S0009.
  • OBJECTIVE: Intraperitoneal (IP) chemotherapy prolongs survival in optimally reduced ovarian cancer patients.
  • For patients in whom optimal debulking cannot be achieved, one could incorporate IP therapy post-operatively if the cancer was optimally debulked following neoadjuvant chemotherapy.
  • METHODS: Women with adenocarcinoma by biopsy or cytology with stage III/IV (pleural effusions only) epithelial ovarian, fallopian tube or primary peritoneal carcinoma that presented with bulky disease were treated with neoadjuvant intravenous (IV) paclitaxel 175 mg/m2 and carboplatin AUC 6 q 21 daysx3 cycles followed by surgery (if >/=50% decrease in CA125).
  • Fifty-six were evaluated for neoadjuvant chemotherapy toxicities.
  • Twenty-six patients received post-cytoreduction chemotherapy.
  • PFS and OS for the 26 patients who received IV/IP chemotherapy is 29 and 34 months respectively.

  • Genetic Alliance. consumer health - Fallopian Tube Cancer.
  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 1990 Jun;37(3):327-31 [2351315.001]
  • [Cites] J Clin Oncol. 1990 Aug;8(8):1335-41 [2199620.001]
  • [Cites] Gynecol Oncol. 1991 Feb;40(2):103-6 [2010101.001]
  • [Cites] Gynecol Oncol. 1991 Aug;42(2):146-50 [1894174.001]
  • [Cites] J Clin Oncol. 1992 Sep;10(9):1485-91 [1355523.001]
  • [Cites] Gynecol Oncol. 1992 Nov;47(2):159-66 [1468693.001]
  • [Cites] J Clin Oncol. 1993 Jan;11(1):166-72 [8418230.001]
  • [Cites] Clin Oncol (R Coll Radiol). 1993;5(4):198-202 [8398914.001]
  • [Cites] Am J Obstet Gynecol. 1994 Apr;170(4):974-9; discussion 979-80 [8166218.001]
  • [Cites] Gynecol Oncol. 1994 Apr;53(1):33-7 [8175019.001]
  • [Cites] Obstet Gynecol Clin North Am. 1994 Mar;21(1):195-212 [8015764.001]
  • [Cites] N Engl J Med. 1995 Mar 9;332(10):629-34 [7845426.001]
  • [Cites] J Clin Oncol. 1995 Dec;13(12):2961-7 [8523061.001]
  • [Cites] N Engl J Med. 1996 Jan 4;334(1):1-6 [7494563.001]
  • [Cites] N Engl J Med. 1996 Dec 26;335(26):1950-5 [8960474.001]
  • [Cites] Gynecol Oncol. 1998 Dec;71(3):431-6 [9887245.001]
  • [Cites] Gynecol Oncol. 1999 Jan;72(1):93-9 [9889037.001]
  • [Cites] N Engl J Med. 2004 Dec 9;351(24):2489-97 [15590951.001]
  • [Cites] Gynecol Oncol. 2005 Apr;97(1):10-5 [15790431.001]
  • [Cites] N Engl J Med. 2006 Jan 5;354(1):34-43 [16394300.001]
  • [Cites] Gynecol Oncol. 2007 Feb;104(2):480-90 [17166564.001]
  • [Cites] Gynecol Oncol. 2008 Feb;108(2):265-70 [18055006.001]
  • [Cites] Gynecol Oncol. 2008 Feb;108(2):271-5 [18164380.001]
  • [Cites] J Clin Oncol. 2000 Jan;18(1):106-15 [10623700.001]
  • [Cites] J Clin Oncol. 2001 Feb 15;19(4):1001-7 [11181662.001]
  • [Cites] Cancer. 2001 Nov 15;92(10):2585-91 [11745193.001]
  • [Cites] Obstet Gynecol. 1983 Apr;61(4):413-20 [6828269.001]
  • [Cites] Cancer Chemother Pharmacol. 1986;18(3):235-8 [3542268.001]
  • [Cites] J Clin Oncol. 1988 Feb;6(2):282-90 [3276825.001]
  • [Cites] Cancer Chemother Pharmacol. 1988;21(1):57-60 [3277734.001]
  • [Cites] Gynecol Oncol. 1988 Jul;30(3):347-58 [3134277.001]
  • [Cites] J Clin Oncol. 1989 Nov;7(11):1748-56 [2681557.001]
  • [Cites] Gynecol Oncol. 1990 Mar;36(3):306-11 [2180794.001]
  • (PMID = 19138791.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA86780; United States / NCI NIH HHS / CA / N01 CA035176; United States / NCI NIH HHS / CA / CA45560; United States / NCI NIH HHS / CA / CA13612; United States / NCI NIH HHS / CA / CA35261; United States / NCI NIH HHS / CA / CA22433; United States / NCI NIH HHS / CA / CA12213; United States / NCI NIH HHS / CA / U10 CA045560; United States / NCI NIH HHS / CA / CA12644; United States / NCI NIH HHS / CA / N01 CA032102; United States / NCI NIH HHS / CA / N01 CA013612; United States / NCI NIH HHS / CA / U10 CA013612; United States / NCI NIH HHS / CA / CA35281; United States / NCI NIH HHS / CA / N01 CA046441; United States / NCI NIH HHS / CA / CA35262; United States / NCI NIH HHS / CA / U10 CA035281; United States / NCI NIH HHS / CA / CA58861; United States / NCI NIH HHS / CA / U10 CA035261; United States / NCI NIH HHS / CA / U10 CA105409; United States / NCI NIH HHS / CA / CA46441; United States / NCI NIH HHS / CA / U10 CA032102; United States / NCI NIH HHS / CA / CA105409; United States / NCI NIH HHS / CA / U10 CA035262; United States / NCI NIH HHS / CA / CA46368; United States / NCI NIH HHS / CA / CA32102; United States / NCI NIH HHS / CA / CA38926; United States / NCI NIH HHS / CA / N01 CA038926; United States / NCI NIH HHS / CA / U10 CA067575; United States / NCI NIH HHS / CA / U10 CA046441; United States / NCI NIH HHS / CA / U10 CA038926; United States / NCI NIH HHS / CA / CA35176; United States / NCI NIH HHS / CA / U10 CA086780; United States / NCI NIH HHS / CA / CA52654; United States / NCI NIH HHS / CA / U10 CA046368; United States / NCI NIH HHS / CA / N01 CA067575; United States / NCI NIH HHS / CA / U10 CA052654; United States / NCI NIH HHS / CA / U10 CA035176; United States / NCI NIH HHS / CA / CA58723; United States / NCI NIH HHS / CA / CA67575; United States / NCI NIH HHS / CA / N01 CA045560
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  • [Other-IDs] NLM/ NIHMS423205; NLM/ PMC3513943
  •  go-up   go-down


Advertisement
4. Varras M, Akrivis Ch, Bellou A, Malamou-Mitsi VD, Antoniou N, Tolis C, Salamalekis E: Primary fallopian tube adenocarcinoma: preoperative diagnosis, treatment and follow-up. Eur J Gynaecol Oncol; 2004;25(5):640-6
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary fallopian tube adenocarcinoma: preoperative diagnosis, treatment and follow-up.
  • Preoperative diagnosis of fallopian tube carcinoma is difficult due to the rarity and silent course of this neoplasm.
  • We present herein the case of a 58-year-old woman with primary fallopian tube carcinoma that was diagnosed preoperatively on the basis of a positive for adenocarcinoma Papanicolaou vaginal smear, repeated episodes of vaginal bleeding, negative endocervical and endometrial curettage, characteristic features on ultrasonography and elevated CA-125 levels.
  • Pathologic confirmation of primary serous papillary adenocarcinoma of the left fallopian tube was made.
  • FIGO stage was considered as IIIb and the patient received six courses of combined carboplatin-taxol chemotherapy.
  • At two years from onset of therapy the patient underwent a modified radical mastectomy and lymphadenectomy because of primary carcinoma of the right breast.
  • The patient was started on tamoxifen therapy, which she is still taking.
  • In conclusion, our study suggests an association between fallopian tube carcinoma and breast cancer and a good response of the patient to platinum-based chemotherapy.
  • [MeSH-major] Breast Neoplasms / diagnosis. Carcinoma, Ductal, Breast / diagnosis. Cystadenocarcinoma, Papillary / diagnosis. Fallopian Tube Neoplasms / diagnosis
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Diagnosis, Differential. Estrogen Antagonists / therapeutic use. Female. Humans. Mastectomy. Middle Aged. Neoplasm Staging. Postoperative Period. Preoperative Care. Tamoxifen / therapeutic use

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15493187.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Estrogen Antagonists; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


5. Cheng X, Moroney JW, Levenback CF, Fu S, Jaishuen A, Kavanagh JJ: What is the benefit of bevacizumab combined with chemotherapy in patients with recurrent ovarian, fallopian tube or primary peritoneal malignancies? J Chemother; 2009 Nov;21(5):566-72
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] What is the benefit of bevacizumab combined with chemotherapy in patients with recurrent ovarian, fallopian tube or primary peritoneal malignancies?
  • The aim of this retrospective analysis was to investigate the efficacy and adverse effects of the monoclonal antivascular endothelial growth factor antibody bevacizumab (Avastin(R)) combined with chemotherapeutic agents in non-protocol patients with recurrent ovarian, fallopian tube, or primary peritoneal malignancies.
  • Using our databases, we identified patients treated with bevacizumab combination therapy since June 2005.
  • The median patient age was 58 years, and they had undergone a median of 4.5 (range, 1-10) prior cytotoxic chemotherapy regimens.
  • A median of 4 cycles of therapy with a median bevacizumab dose of 3,600 mg (range, 500-18,240) were administered.
  • Bevacizumab combined with chemotherapy showed promising clinical benefits, with significant response of serum CA125 concentration and moderate adverse effects.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Fallopian Tube Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy. Ovarian Neoplasms / drug therapy. Peritoneal Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma, Clear Cell / drug therapy. Adenocarcinoma, Clear Cell / secondary. Adenocarcinoma, Mucinous / drug therapy. Adenocarcinoma, Mucinous / secondary. Adult. Aged. Antibodies, Monoclonal, Humanized. Bevacizumab. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Cystadenocarcinoma, Serous / drug therapy. Cystadenocarcinoma, Serous / secondary. Drug Therapy, Combination. Female. Humans. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Rate. Taxoids / administration & dosage. Taxoids / adverse effects. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19933049.001).
  • [ISSN] 1973-9478
  • [Journal-full-title] Journal of chemotherapy (Florence, Italy)
  • [ISO-abbreviation] J Chemother
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Taxoids; 2S9ZZM9Q9V / Bevacizumab; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


6. Gemignani ML, Hensley ML, Cohen R, Venkatraman E, Saigo PE, Barakat RR: Paclitaxel-based chemotherapy in carcinoma of the fallopian tube. Gynecol Oncol; 2001 Jan;80(1):16-20
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paclitaxel-based chemotherapy in carcinoma of the fallopian tube.
  • OBJECTIVE: The objective of this study was to determine the clinical outcomes of patients with fallopian tube carcinoma treated with paclitaxel-based combination chemotherapy following primary cytoreductive surgery.
  • METHODS: Twenty-four patients with the diagnosis of primary tubal adenocarcinoma treated between 1993 and 1998 were identified through the gynecology service database and the Memorial Sloan-Kettering Cancer Center tumor registry.
  • Medical records were reviewed for information on age, stage, chemotherapy regimen, surgical intervention, relapse, and survival.
  • All patients had their histologic material initially read or reviewed at Memorial Sloan-Kettering Cancer Center prior to treatment.
  • The original slides were reviewed again by one of the authors (P.E.S.) to confirm the diagnosis of primary fallopian tube cancer.
  • Sixteen patients (67%) had optimal cytoreduction at the time of initial surgery with residual disease less than 1 cm.
  • Following initial surgery, all patients were treated with paclitaxel-based chemotherapy for a median of five cycles.
  • Median follow-up from time of initial surgery was 24 months (range, 1-73 months).
  • CONCLUSION: Optimally cytoreduced patients with primary fallopian tube carcinoma treated with a paclitaxel-based chemotherapy regimen have an excellent possibility of survival.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Fallopian Tube Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Carboplatin / administration & dosage. Cisplatin / administration & dosage. Combined Modality Therapy. Disease-Free Survival. Female. Follow-Up Studies. Humans. Middle Aged. Paclitaxel / administration & dosage. Survival Rate

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 Academic Press.
  • [CommentIn] Gynecol Oncol. 2002 Jan;84(1):185-6 [11749002.001]
  • (PMID = 11136563.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


7. Alduaij A, Hansen K, Zhang C: Primary follicular lymphoma of the fallopian tube found incidentally in a patient treated for endometrial carcinoma: a case report. Diagn Pathol; 2010;5:44
MedlinePlus Health Information. consumer health - Hysterectomy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary follicular lymphoma of the fallopian tube found incidentally in a patient treated for endometrial carcinoma: a case report.
  • We report a rare case of primary lymphoma of fallopian tube in a 68-year-old woman who underwent total hysterectomy and bilateral salpingo-oophorectomy for endometrial carcinoma.
  • The specimen showed a well-differentiated endometrioid adenocarcinoma with superficial myometrial invasion.
  • The left fallopian tube revealed a 1 cm nodule that histologically showed diffuse lymphoid follicles consisting of small cleaved lymphocytes and occasional larger cells.
  • The findings were consistent with a primary low grade follicular lymphoma of fallopian tube.
  • She did not receive chemotherapy and remained disease free for 13 months after surgery.
  • Our case suggests that primary lymphoma of fallopian tube may be associated with a favorable prognosis.
  • [MeSH-major] Carcinoma, Endometrioid / surgery. Endometrial Neoplasms / surgery. Fallopian Tube Neoplasms / pathology. Hysterectomy. Incidental Findings. Lymphoma, Follicular / pathology. Neoplasms, Multiple Primary. Ovariectomy
  • [MeSH-minor] Aged. Biomarkers, Tumor / analysis. Female. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Intraoperative Period. Translocation, Genetic. Treatment Outcome

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 2002 Sep;86(3):384-6 [12217767.001]
  • [Cites] Cancer. 1983 Nov 15;52(10):1933-43 [6627208.001]
  • [Cites] Int J Gynecol Pathol. 2006 Jan;25(1):1-21 [16306779.001]
  • [Cites] Int J Gynecol Pathol. 1991;10(4):394-401 [1774110.001]
  • [Cites] Gynecol Oncol. 2004 Dec;95(3):736-8 [15581994.001]
  • [Cites] Pathol Annu. 1991;26 Pt 1:227-63 [2014141.001]
  • (PMID = 20584306.001).
  • [ISSN] 1746-1596
  • [Journal-full-title] Diagnostic pathology
  • [ISO-abbreviation] Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ PMC2905343
  •  go-up   go-down


8. Matsuo K, Bond VK, Eno ML, Im DD, Rosenshein NB: Low drug resistance to both platinum and taxane chemotherapy on an in vitro drug resistance assay predicts improved survival in patients with advanced epithelial ovarian, fallopian and peritoneal cancer. Int J Cancer; 2009 Dec 1;125(11):2721-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low drug resistance to both platinum and taxane chemotherapy on an in vitro drug resistance assay predicts improved survival in patients with advanced epithelial ovarian, fallopian and peritoneal cancer.
  • The objective of this study was to evaluate the role of an in vitro drug resistance assay to platinum and taxane in the management of advanced epithelial ovarian, fallopian and primary peritoneal cancer.
  • All patients with FIGO Stage IIIc and IV who received postoperative chemotherapy with platinum and taxane for more than 4 courses after the initial cytoreductive surgery between 1995 and 2008 were evaluated.
  • Patients who received neoadjuvant chemotherapy were not included.
  • An in vitro drug resistance assay (EDR Assay, Oncotech, Tustin, CA) was used to determine drug resistance for each patient's tumor tissue.
  • Level of drug resistance was described as extreme (EDR), intermediate (IDR), or low (LDR).
  • Response to chemotherapy and survival were correlated to the EDR Assay.
  • In conclusion, LDR to both platinum and taxane chemotherapy, as determined by an in vitro drug resistance assay, independently predicts improved survival in patients with advanced epithelial ovarian, fallopian and peritoneal cancer, especially in those patients who undergo optimal primary cytoreduction.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biological Assay / methods. Drug Resistance, Neoplasm. Fallopian Tube Neoplasms / drug therapy. Ovarian Neoplasms / drug therapy. Peritoneal Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma, Clear Cell / drug therapy. Adenocarcinoma, Clear Cell / mortality. Adenocarcinoma, Clear Cell / secondary. Bridged Compounds / administration & dosage. Cystadenocarcinoma, Serous / drug therapy. Cystadenocarcinoma, Serous / mortality. Cystadenocarcinoma, Serous / secondary. Endometrial Neoplasms / drug therapy. Endometrial Neoplasms / mortality. Endometrial Neoplasms / secondary. Female. Humans. In Vitro Techniques. Lymphatic Metastasis. Middle Aged. Organoplatinum Compounds / administration & dosage. Prognosis. Retrospective Studies. Survival Rate. Taxoids / administration & dosage


9. Inal MM, Hanhan M, PIlanci B, Tinar S: Fallopian tube malignancies: experience of Social Security Agency Aegean Maternity Hospital. Int J Gynecol Cancer; 2004 Jul-Aug;14(4):595-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fallopian tube malignancies: experience of Social Security Agency Aegean Maternity Hospital.
  • The aim of the study was to determine the clinical characteristics and management of fallopian tube malignancies together with the results there unto that had been diagnosed and treated in our oncology department retrospectively.
  • Twelve cases of fallopian tube malignancies, of a total of 2155 gynecologic malignancies (0.55%), that had been diagnosed in or referred to our hospital between January 1986 and December 2001 were evaluated retrospectively.
  • Adjuvant chemotherapy was applied to all of the cases except two (10 cases, 83.3%).
  • Histopathology of the cases was as follows: serous adenocarcinoma in 10 cases (83.3%), endometrioid adenocarcinoma in one case (8.3%), and undifferentiated carcinoma in one case (8.3%).
  • Adjuvant chemotherapy (PAC regimen to eight of the cases and PP regimen to two cases) was applied to 10 of the cases (83.3%).
  • Fallopian tube malignancies are very rare malignancies.
  • [MeSH-major] Adenocarcinoma / therapy. Fallopian Tube Neoplasms / therapy. Gynecologic Surgical Procedures / methods. Hospitals, Maternity
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / therapeutic use. Female. Humans. Middle Aged. Neoplasm Staging. Retrospective Studies. Turkey

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15304152.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


10. Raff JP, Anderson P, Sands C, Makower D: Fallopian tube carcinoma presenting with a brain metastasis. Gynecol Oncol; 2002 May;85(2):372-5
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fallopian tube carcinoma presenting with a brain metastasis.
  • BACKGROUND: Fallopian tube carcinoma is a rare gynecologic cancer.
  • An extensive literature search reveals no previous case report of fallopian tube carcinoma presenting with a brain metastasis.
  • The patient underwent a complete resection, followed by whole-brain radiation therapy.
  • Pathologic review demonstrated adenocarcinoma with follicular structures.
  • She underwent resection of a large fallopian tube carcinoma with normal ovaries.
  • She recovered from surgery and is receiving combination chemotherapy.
  • CONCLUSION: This is the first case report of a fallopian tube carcinoma presenting as a brain metastasis.
  • [MeSH-major] Brain Neoplasms / secondary. Fallopian Tube Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2002 Elsevier Science (USA).
  • (PMID = 11972403.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Piura B, Meirovitz M: Weekly single-agent carboplatin in heavily pretreated patients with recurrent ovarian, peritoneal and fallopian tube carcinoma. Eur J Gynaecol Oncol; 2005;26(4):386-90
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Weekly single-agent carboplatin in heavily pretreated patients with recurrent ovarian, peritoneal and fallopian tube carcinoma.
  • PURPOSE OF INVESTIGATION: To report the experience of a single institution in the south of Israel with weekly carboplatin in heavily pretreated patients with platinum-sensitive recurrent ovarian, peritoneal and fallopian tube carcinoma.
  • METHODS: The hospital records of ten patients with platinum-sensitive recurrent ovarian, peritoneal and fallopian tube carcinoma who had 2nd-line or later chemotherapy with weekly carboplatin between January 2003 and December 2004 were retrospectively reviewed.
  • Toxicity was graded using the National Cancer Institute (NCI) criteria.
  • The median number of courses per patient was 14 (range, 2-37) and median duration of treatment was 22.5 (range, 2-40) weeks.
  • CONCLUSION: Weekly carboplatin has considerable activity and low and well tolerated toxicity in heavily pretreated patients with platinum-sensitive recurrent ovarian, peritoneal and fallopian tube carcinoma.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / administration & dosage. Carboplatin / administration & dosage. Fallopian Tube Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy. Ovarian Neoplasms / drug therapy. Peritoneal Neoplasms / drug therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Drug Administration Schedule. Female. Gynecologic Surgical Procedures. Humans. Middle Aged. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16122184.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents; BG3F62OND5 / Carboplatin
  •  go-up   go-down


12. Micha JP, Goldstein BH, Rettenmaier MA, Mattison J, Graham C, Birk CL, Brown JV: Pilot study of outpatient paclitaxel, carboplatin and gemcitabine for advanced stage epithelial ovarian, peritoneal, and fallopian tube cancer. Gynecol Oncol; 2004 Sep;94(3):719-24
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pilot study of outpatient paclitaxel, carboplatin and gemcitabine for advanced stage epithelial ovarian, peritoneal, and fallopian tube cancer.
  • OBJECTIVE: The purpose of this study was to determine the feasibility, response rate, and toxicity of paclitaxel, carboplatin, and gemcitabine as an outpatient regimen in the treatment of ovarian/non-ovarian and tubal adenocarcinoma.
  • This is the largest completed study using this regimen as first-line treatment of these patients.
  • After six cycles of treatment, responders were eligible for an additional three cycles of paclitaxel and gemcitabine.
  • RESULTS: Fifty-seven patients (median age = 58; range 41-81) with stage III/IV epithelial carcinoma of the ovary, fallopian tube, and peritoneum received a total of 476 cycles of chemotherapy.
  • Grades 3 and 4 neutropenia developed in 19.7% and 9% of cycles while grades 3 and 4 thrombocytopenia developed in 4.2% and 1.3% of the cycles.
  • Twenty-two patients developed some degree of neuropathy, although there was no reported interference with activities of daily living.
  • CONCLUSIONS: This report represents the largest completed study in the world employing this triplet regimen in the first-line treatment of advanced stage epithelial ovarian, fallopian tube, or peritoneal cancer patients.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Deoxycytidine / analogs & derivatives. Fallopian Tube Neoplasms / drug therapy. Ovarian Neoplasms / drug therapy. Peritoneal Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carboplatin / administration & dosage. Carboplatin / adverse effects. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Middle Aged. Neoplasm Staging. Paclitaxel / administration & dosage. Paclitaxel / adverse effects. Pilot Projects


13. Scholz HS, Lax S, Tamussino KF, Benedicic C, Petru E: Long-term survival of a patient with fallopian tube cancer presenting with a supraclavicular mass. Anticancer Res; 2000 Nov-Dec;20(6C):4801-2
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term survival of a patient with fallopian tube cancer presenting with a supraclavicular mass.
  • BACKGROUND: Five-year survival of patients with stage IV cancer of the fallopian tube is poor.
  • The mass was removed and histology showed metastatic papillary adenocarcinoma strongly suggestive of papillary serous carcinoma.
  • Abdominal hysterectomy and salpingo-oophorectomy showed a primary carcinoma of the fallopian tube.
  • Postoperatively the patient received six cycles of carboplatin-based chemotherapy and is alive and well with no evidence of disease 5 years and 10 months after the primary diagnosis.
  • CONCLUSION: Surgery and adjuvant carboplatin-based chemotherapy seem justified even in older patients with fallopian tube cancer and distant metastasis at the time of diagnosis.
  • [MeSH-major] Adenocarcinoma, Papillary / drug therapy. Adenocarcinoma, Papillary / surgery. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Fallopian Tube Neoplasms / drug therapy. Fallopian Tube Neoplasms / surgery
  • [MeSH-minor] Aged. Carboplatin / administration & dosage. Chemotherapy, Adjuvant. Clavicle. Cyclophosphamide / administration & dosage. Female. Humans. Hysterectomy. Neoplasm Metastasis. Ovariectomy. Survivors. Time Factors

  • Genetic Alliance. consumer health - Fallopian Tube Cancer.
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11205221.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 8N3DW7272P / Cyclophosphamide; BG3F62OND5 / Carboplatin
  •  go-up   go-down


14. Sonmezer M, Ustun Y, Gungor M, Ensari A, Ortac F: Primary carcinoma of the fallopian tube in a 88 years old woman: review of the literature. Indian J Cancer; 2001 Jun-Dec;38(2-4):61-4
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary carcinoma of the fallopian tube in a 88 years old woman: review of the literature.
  • A woman of 88 years old with primary carcinoma of the fallopian tube, the oldest patient reported in the English literature according to the best of our knowledge, was presented.
  • After debulking surgery four courses of chemotherapy including paclitaxel and carboplatin was performed.
  • [MeSH-major] Adenocarcinoma / pathology. Fallopian Tube Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Antineoplastic Agents, Phytogenic / therapeutic use. CA-125 Antigen / blood. Diagnosis, Differential. Female. Humans. Hysterectomy. Paclitaxel / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12593439.001).
  • [ISSN] 0019-509X
  • [Journal-full-title] Indian journal of cancer
  • [ISO-abbreviation] Indian J Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / CA-125 Antigen; P88XT4IS4D / Paclitaxel
  • [Number-of-references] 10
  •  go-up   go-down


15. Rose PG, Drake R, Braly PS, Bell MC, Wenham RM, Hines JH, Alvarez-Secord A, Soltes-Rak E, Childs BH, Herzog TJ: Preliminary results of a phase II study of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum, and fallopian tube. J Clin Oncol; 2009 May 20;27(15_suppl):5546

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preliminary results of a phase II study of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum, and fallopian tube.
  • : 5546 Background: Objectives are to estimate efficacy and safety of a novel taxane/platinum chemotherapy doublet in combination with bevacizumab (B), as first-line treatment of advanced cancer of the ovary, peritoneum or fallopian tube (FT), after initial debulking surgery.
  • Subjects were treated with 6 cycles of oxaliplatin (85 mg/m2), docetaxel (75 mg/m2) and B (15 mg/kg) Q3W, followed by maintenance B (15 mg/kg Q3W) to complete one year of therapy.
  • Tumors were mostly ovary as primary site (84%), poorly differentiated (65%), serous adenocarcinoma pathology (73%) and FIGO stage IIIC (68.2%) or IV (14.6%).
  • 95 (86%) of subjects had completed the chemotherapy cycles with 87 of the 95 having started on the B-only maintenance cycles.
  • 85 (77%) subjects have stopped study treatment [including 33 completed study treatment, 29 disease progression, 15 adverse event (AE), 8 other reasons].

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962510.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Baekelandt M, Jorunn Nesbakken A, Kristensen GB, Tropé CG, Abeler VM: Carcinoma of the fallopian tube. Cancer; 2000 Nov 15;89(10):2076-84

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carcinoma of the fallopian tube.
  • BACKGROUND: The objective of the current study was to increase insight into the biology of fallopian tube carcinoma through an analysis of possible clinical and pathologic determinants of prognosis and to formulate recommendations with regard to a more optimal therapeutic approach for patients with this rare disease.
  • METHODS: A study was performed of the pathology specimens and clinical case records from 151 patients with fallopian tube carcinoma who were treated consecutively.
  • The possible significance of serum CA-125 levels as a tumor marker and a marker of response to platinum-containing chemotherapy was evaluated.
  • RESULTS: In multivariate analysis, disease stage, the presence of residual tumor, and a hydrosalpinx-like appearance of the fallopian tube were of independent prognostic significance for the whole cohort.
  • In 37 evaluable, platinum-naïve patients, an overall response rate of 70% was obtained with platinum-based chemotherapy, with a median response duration of 12.5 months.
  • In view of its low efficacy and high rate of serious complications, the use of postoperative radiotherapy in the treatment of patients with fallopian tube carcinoma is no longer recommended.
  • Serum CA-125 level measurements in fallopian tube carcinoma patients have the same significance as tumor and surrogate markers of response as in ovarian carcinoma patients.
  • CONCLUSIONS: Prognostic factors in patients with early stage (Stages 0 and I) fallopian tube carcinoma seem to differ from those in patients with early stage ovarian carcinoma.
  • For patients with more advanced stage disease, due to the striking similarities in prognostic and clinical characteristics between the two diseases, the authors recommend that the treatment and follow-up strategies for patients with ovarian carcinoma be adopted in the management of patients with fallopian tube carcinoma.
  • [MeSH-major] Adenocarcinoma / diagnosis. Fallopian Tube Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 American Cancer Society.
  • (PMID = 11066048.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


17. Osmanağaoğlu MA, Bozkaya H, Cobanoğlu U: Primary adenocarcinoma of the fallopian tube: a case report. Eur J Gynaecol Oncol; 2004;25(6):755-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary adenocarcinoma of the fallopian tube: a case report.
  • We report a case of a 75-year-old postmenopausal woman with primary fallopian tube carcinoma confined to the left fallopian tube in Stage IA-2, who is alive without evidence of disease three years after total abdominal hysterectomy, bilateral salpingo-oophorectomy, total omentectomy, pelvic and paraaortic lymph node dissection were performed.
  • Histopathological examination revealed a poorly differentiated (grade 3) papillary serous adenocarcinoma of the left fallopian tube.
  • Primary fallopian cancer should be suspected by clinicians even if the presenting symptoms are atypical and the primary treatment remains surgical resection followed by adjuvant chemotherapy or radiation.
  • Appropriate therapy for each stage of the disease should be defined and new studies are needed to better depict the clinical course and prognostic factors.
  • [MeSH-major] Adenocarcinoma / diagnosis. Fallopian Tube Neoplasms / diagnosis
  • [MeSH-minor] Aged. Combined Modality Therapy. Diagnosis, Differential. Female. Humans. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15597861.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


18. Liapis A, Bakalianou K, Mpotsa E, Salakos N, Fotiou S, Kondi-Paffiti A: Fallopian tube malignancies: A retrospective clinical pathological study of 17 cases. J Obstet Gynaecol; 2008 Jan;28(1):93-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fallopian tube malignancies: A retrospective clinical pathological study of 17 cases.
  • The histological type of all our specimens was primary papillary adenocarcinoma of the fallopian tube.
  • Primary fallopian tube cancer (PFTC) is a rare gynaecological malignancy, similar to ovarian cancer, but with poorer prognosis.
  • The treatment was surgical followed by adjuvant chemotherapy.
  • [MeSH-major] Adenocarcinoma, Papillary / epidemiology. Fallopian Tube Neoplasms / epidemiology
  • [MeSH-minor] Aged. Combined Modality Therapy. Databases, Factual. Female. Greece / epidemiology. Humans. Medical Records. Middle Aged. Neoplasm Staging. Pathology Department, Hospital. Pregnancy. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18259909.001).
  • [ISSN] 1364-6893
  • [Journal-full-title] Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology
  • [ISO-abbreviation] J Obstet Gynaecol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


19. Khan Y, Haq AN, Nasar R: Primary fallopian tube carcinoma presenting with a sinus in the posterior portion of cervix. Int J Gynecol Cancer; 2004 Jan-Feb;14(1):166-8
MedlinePlus Health Information. consumer health - Fistulas.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary fallopian tube carcinoma presenting with a sinus in the posterior portion of cervix.
  • Primary fallopian tube carcinoma is an aggressive but rare tumor.
  • Surgical resection was followed by adjuvant chemotherapy.
  • The patient is doing well after the therapy.
  • [MeSH-major] Adenocarcinoma, Papillary / diagnosis. Fallopian Tube Neoplasms / diagnosis. Fistula / diagnosis. Uterine Cervical Diseases / diagnosis

  • MedlinePlus Health Information. consumer health - Cervix Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14764047.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Deliveliotou A, Hassiakos D, Fotiou S, Karvouni E, Creatsas G: Primary fallopian tube carcinoma associated with ovulation induction; a case report. Int J Gynecol Cancer; 2008 Nov-Dec;18(6):1360-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary fallopian tube carcinoma associated with ovulation induction; a case report.
  • The potential relationship between ovulation induction and gynecological cancer has been raised recently.
  • Primary fallopian tube carcinoma (PFTC) is an uncommon malignancy, not previously associated with fertility drugs use.
  • We describe a case of a 38-year-old woman with primary infertility and a history of three ovulation inductions with gonadotropin-releasing hormone agonist and gonadotrophins, referred for treatment of bilateral ovarian cysts, which were discovered in the beginning of the last cycle.
  • Histologic examination showed a primary right fallopian tube endometrioid adenocarcinoma and bilateral adnexal endometriosis.
  • Surgery was followed by six cycles of combination chemotherapy using paclitaxel and carboplatin without significant complications.
  • Although evidence of a direct causal link between ovarian stimulation and PFTC does not yet exist, this case highlights the importance for careful evaluation of all discovered adnexal masses in women undergoing ovulation induction treatment.
  • [MeSH-major] Fallopian Tube Neoplasms / pathology. Ovulation Induction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18217974.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Singhal P, Odunsi K, Rodabaugh K, Driscoll D, Lele S: Primary fallopian tube carcinoma: a retrospective clinicopathologic study. Eur J Gynaecol Oncol; 2006;27(1):16-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary fallopian tube carcinoma: a retrospective clinicopathologic study.
  • INTRODUCTION: Primary fallopian tube carcinoma is a rare tumor.
  • The aim of this study was to evaluate clinical characteristics and management of fallopian tube malignancies at a large tertiary care cancer institute.
  • METHODS: A retrospective review of the Tumor Registry was conducted to identify all primary fallopian tube carcinomas between 1980 and 2001.
  • RESULTS: Thirty-five patients had histology consistent with fallopian tube carcinoma.
  • The most common histology was adenocarcinoma in 16 (46%) patients.
  • Thirty-two (91%) patients received adjuvant chemotherapy and 77% received platinum-based chemotherapy.
  • CONCLUSIONS: Fallopian tube malignancies are rare and carry a poor prognosis.
  • More extensive research needs to be performed to have definitive etiologic, diagnostic and treatment guidelines.
  • [MeSH-major] Carcinoma / mortality. Carcinoma / pathology. Cause of Death. Fallopian Tube Neoplasms / mortality. Fallopian Tube Neoplasms / pathology. Second-Look Surgery / trends
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy, Needle. Combined Modality Therapy. Female. Gynecologic Surgical Procedures / methods. Humans. Immunohistochemistry. Middle Aged. Neoplasm Staging. Probability. Prognosis. Registries. Retrospective Studies. Risk Assessment. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16550961.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


22. Escobar PF, Markman M, Rose P, Zanotti K, Webster K, Belinson J: Phase 2 trial of carboplatin, paclitaxel, and irinotecan in ovarian, fallopian tube, and primary peritoneal cancers. Gynecol Oncol; 2004 Jan;92(1):192-6
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase 2 trial of carboplatin, paclitaxel, and irinotecan in ovarian, fallopian tube, and primary peritoneal cancers.
  • OBJECTIVE: Our goal in this nonrandomized phase 2 trial was to evaluate the toxicity and obtain preliminary data on the potential efficacy of a novel three-drug combination regimen (carboplatin-paclitaxel-irinotecan) when employed as initial therapy of advanced ovarian cancer or as second-line treatment in the setting of a prolonged (>or=12 months) treatment-free interval.
  • METHODS: Patients with a histologically confirmed diagnosis of advanced ovarian cancer, primary adenocarcinoma of the peritoneum, or fallopian tube cancer were enrolled in the study.
  • The three-drug combination was initially administered on an every 21-day schedule, but due to toxicity was subsequently changed to a 28-day program.
  • Twenty-three patients were chemotherapy naive, while 7 had received prior chemotherapy.
  • Seventeen patients completed all six cycles of treatment.
  • CONCLUSIONS: The combination of carboplatin-paclitaxel-irinotecan can be administered to women with advanced ovarian cancer with significant, but overall acceptable toxicity.
  • Defining a place for this three-drug program in the standard management of ovarian cancer will require the conduct of an appropriately designed randomized trial.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Camptothecin / analogs & derivatives. Fallopian Tube Neoplasms / drug therapy. Ovarian Neoplasms / drug therapy. Peritoneal Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Carboplatin / administration & dosage. Carboplatin / adverse effects. Drug Administration Schedule. Female. Humans. Infusions, Intravenous. Middle Aged. Paclitaxel / administration & dosage. Paclitaxel / adverse effects

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14751157.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 7673326042 / irinotecan; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


23. Newton HB, Stevens C, Santi M: Brain metastases from fallopian tube carcinoma responsive to intra-arterial carboplatin and intravenous etoposide: a case report. J Neurooncol; 2001 Dec;55(3):179-84
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brain metastases from fallopian tube carcinoma responsive to intra-arterial carboplatin and intravenous etoposide: a case report.
  • Fallopian tube carcinoma is the least common neoplasm of the female genital tract.
  • It remains unclear, however, what role chemotherapy has in the treatment of these patients and what route of administration is most effective.
  • Intra-arterial (IA) regional administration of chemotherapy may increase intra-tumoral drug concentrations and improve efficacy.
  • We report the case of a 47-year-old woman who developed bilateral fallopian tube cancer and multifocal brain metastases.
  • After progression through radiation therapy and oral chemotherapy, she was placed on IA carboplatin (200 mg/m2/d x 2 days every 4 weeks) and intravenous etoposide (100 mg/m2/d x 2 days every 4 weeks).
  • During treatment she had objective tumor shrinkage that has remained stable for more than 12 months.
  • For patients with fallopian tube carcinoma that develop brain metastases and respond poorly to surgery and/or irradiation, multi-agent chemotherapy containing carboplatin should be considered.
  • [MeSH-major] Adenocarcinoma, Papillary / secondary. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / secondary. Brain Stem / pathology. Fallopian Tube Neoplasms / pathology. Temporal Lobe / pathology
  • [MeSH-minor] Antineoplastic Agents, Alkylating / therapeutic use. Carboplatin / administration & dosage. Carotid Arteries. Cisplatin / administration & dosage. Combined Modality Therapy. Cranial Irradiation. Cyclophosphamide / administration & dosage. Dacarbazine / analogs & derivatives. Dacarbazine / therapeutic use. Etoposide / administration & dosage. Fallopian Tubes / injuries. Female. Humans. Infusions, Intra-Arterial. Infusions, Intravenous. Magnetic Resonance Imaging. Middle Aged. Paclitaxel / administration & dosage. Physical Examination / adverse effects. Rupture, Spontaneous. Vertebral Artery

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Pharmacother. 1999 Jul-Aug;33(7-8):816-32 [10466912.001]
  • [Cites] Oncology (Williston Park). 1989 Oct;3(10):20-6; discussion 26-7, 30, 32 [2701210.001]
  • [Cites] Radiology. 1999 Oct;213(1):135-40 [10540653.001]
  • [Cites] Med Oncol. 1998 Apr;15(1):6-14 [9643524.001]
  • [Cites] Am Fam Physician. 1999 Feb 15;59(4):878-86 [10068711.001]
  • [Cites] J Clin Oncol. 1992 Oct;10(10):1553-60 [1383433.001]
  • [Cites] Expert Opin Investig Drugs. 2000 Dec;9(12):2815-29 [11093355.001]
  • [Cites] Cancer. 2000 Feb 1;88(3):637-47 [10649259.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Jan 1;40(1):71-6 [9422560.001]
  • [Cites] Cancer. 1999 Apr 1;85(7):1599-605 [10193952.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Mar 1;37(4):745-51 [9128946.001]
  • [Cites] Cancer. 1992 Feb 15;69(4):972-80 [1735089.001]
  • [Cites] Neurosurg Clin N Am. 1996 Jul;7(3):527-36 [8823780.001]
  • [Cites] Cancer. 2000 Nov 15;89(10):2076-84 [11066048.001]
  • (PMID = 11859973.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 16058
  • [Publication-type] Case Reports; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 6PLQ3CP4P3 / Etoposide; 7GR28W0FJI / Dacarbazine; 8N3DW7272P / Cyclophosphamide; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; YF1K15M17Y / temozolomide
  •  go-up   go-down


24. Wagenaar HC, Pecorelli S, Vergote I, Curran D, Wagener DJ, Kobierska A, Bolis G, Bokkel-Huinink WT, Lacave AJ, Madronal C, Forn M, de Oliveira CF, Mangioni C, Nooij MA, Goupil A, Kerbrat P, Marth CH, Tumolo S, Herben MG, Zanaboni F, Vermorken JB: Phase II study of a combination of cyclophosphamide, adriamycin and cisplatin in advanced fallopian tube carcinoma. An EORTC gynecological cancer group study. European Organization for Research and Treatment of Cancer. Eur J Gynaecol Oncol; 2001;22(3):187-93
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of a combination of cyclophosphamide, adriamycin and cisplatin in advanced fallopian tube carcinoma. An EORTC gynecological cancer group study. European Organization for Research and Treatment of Cancer.
  • OBJECTIVE: To investigate the clinical activity and toxicity of a combination chemotherapy consisting of cyclophosphamide (C), adriamycin (A) and cisplatin (P) for patients with primary adenocarcinoma of the Fallopian tube having FIGO stage III-IV disease.
  • RESULTS: Twenty-four eligible patients with histologically-confirmed Fallopian tube adenocarcinoma were entered in the trial.
  • The median time to progression was 13 months for all patients.
  • CONCLUSION: The present data confirm the therapeutic activity of the CAP-regimen in primary Fallopian tube adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Fallopian Tube Neoplasms / drug therapy
  • [MeSH-minor] Aged. Antibiotics, Antineoplastic / administration & dosage. Antineoplastic Agents, Alkylating / administration & dosage. Cisplatin / administration & dosage. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Drug Administration Schedule. Europe. Female. Humans. Middle Aged. Neoplasm Staging. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Fallopian Tube Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11501769.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antineoplastic Agents, Alkylating; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


25. Neji K, Ben Amara F, Mbarek M, Trabelsi S, Mourali M, Reziga H: [Primitive adenocarcinoma of the fallopian tube: a case report]. Tunis Med; 2004 Feb;82(2):237-40

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primitive adenocarcinoma of the fallopian tube: a case report].
  • His treatment is radical surgery by laparoscopy associated with chemotherapy.
  • The prognosis is correlated with cancer stage and residual tumoral volume after surgery.
  • Definitive histology answered tubal cancer.
  • [MeSH-major] Adenocarcinoma / pathology. Fallopian Tube Neoplasms / pathology. Laparoscopy
  • [MeSH-minor] Fatal Outcome. Female. Humans. Middle Aged. Neoplasm Metastasis. Prognosis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15185603.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Tunisia
  •  go-up   go-down


26. Berry E, Matthews KS, Singh DK, Buttin BM, Lurain JR, Alvarez RD, Schink J: An outpatient intraperitoneal chemotherapy regimen for advanced ovarian cancer. Gynecol Oncol; 2009 Apr;113(1):63-7
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An outpatient intraperitoneal chemotherapy regimen for advanced ovarian cancer.
  • OBJECTIVES: To assess the feasibility, associated toxicities, and reasons for early cessation of an outpatient intraperitoneal (IP) chemotherapy regimen for treatment of advanced ovarian cancer following optimal cytoreductive surgery.
  • METHODS: Between January 2006 and December 2007, 42 patients with stages IIC-IV epithelial ovarian, tubal, or primary peritoneal cancer who had residual disease <1 cm after cytoreductive surgery were treated with an outpatient IP chemotherapy protocol.
  • Patients received intravenous (IV) docetaxel 75 mg/m(2) and IP cisplatin 75-100 mg/m(2) on day 1, followed by IP paclitaxel 60 mg/m(2) on day 8, with the intent to treat patients every 21 days for 6 cycles of chemotherapy.
  • Charts were abstracted for demographic, chemotherapy, and toxicity-related data.
  • RESULTS: The median age of the 42 patients was 59 years (range 33-70) and the majority of patients had epithelial ovarian cancer (80%), FIGO stage IIIC (83%), and papillary serous histology (74%).
  • Of an intended 252 IP chemotherapy cycles, 172 (68%) were administered.
  • There was one treatment-related death.
  • Reasons for discontinuation were largely chemotherapy (43%) or port (37%) related.
  • CONCLUSIONS: With supportive measures, such as scheduled hydration and granulocyte colony-stimulating factors, outpatient administration of IP chemotherapy was feasible.
  • This regimen resulted in few hospitalizations or treatment delays and demonstrated less toxicity than previously reported IP chemotherapy regimens.
  • Port-related complications were a leading cause of IP chemotherapy discontinuation.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Adult. Aged. Amifostine / administration & dosage. Cisplatin / administration & dosage. Combined Modality Therapy. Fallopian Tube Neoplasms / drug therapy. Fallopian Tube Neoplasms / pathology. Fallopian Tube Neoplasms / surgery. Female. Humans. Infusions, Parenteral. Middle Aged. Neoplasm Staging. Outpatients. Paclitaxel / administration & dosage. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / pathology. Peritoneal Neoplasms / surgery. Pilot Projects. Retrospective Studies

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. AMIFOSTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19201457.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] M487QF2F4V / Amifostine; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


27. Micha JP, Goldstein BH, Rettenmaier MA, Genesen M, Graham C, Bader K, Lopez KL, Nickle M, Brown JV 3rd: A phase II study of outpatient first-line paclitaxel, carboplatin, and bevacizumab for advanced-stage epithelial ovarian, peritoneal, and fallopian tube cancer. Int J Gynecol Cancer; 2007 Jul-Aug;17(4):771-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of outpatient first-line paclitaxel, carboplatin, and bevacizumab for advanced-stage epithelial ovarian, peritoneal, and fallopian tube cancer.
  • The purpose of this study was to assess the response rate and toxicity of paclitaxel, carboplatin, and bevacizumab (PCB) primary induction therapy for the treatment of advanced-stage ovarian carcinoma.
  • Patients received 116 cycles of PCB chemotherapy (median = 6, range 2-6) and were evaluable for toxicity assessment.
  • Grade 3 and 4 neutropenia developed in 23.3% and 25% of cycles, with no incidence of grades 3/4 thrombocytopenia or anemia.
  • Eighteen patients were evaluated for response following induction therapy.
  • This study suggests that first-line treatment with PCB can be safely administered to previously untreated advanced-stage ovarian carcinoma patients.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Fallopian Tube Neoplasms / drug therapy. Ovarian Neoplasms / drug therapy. Peritoneal Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Fallopian Tube Cancer.
  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17343605.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 2S9ZZM9Q9V / Bevacizumab; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


28. Abdulhathi MB, Al-Salam S, Kassis A, Ghazal-Aswad S: Unusual presentation of cervical cancer as advanced ovarian cancer. Arch Gynecol Obstet; 2007 Oct;276(4):387-90
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual presentation of cervical cancer as advanced ovarian cancer.
  • We report a case of cervical adenocarcinoma presenting primarily as advanced ovarian cancer with the primary site totally silent.
  • Initial investigations with abdominal ultrasound and computerized tomography scan suggested right ovarian dermoid cyst.
  • Surprisingly, the histologic features of the specimen obtained at laparotomy were consistent with a moderately differentiated cervical adenocarcinoma with metastases to corpus uterus, ovaries, left fallopian tube, omentum and pleural cavity.
  • The final stage was stage IV cervical cancer.
  • Following this, the patient was referred to medical oncologist for chemotherapy.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / secondary. Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / secondary. Uterine Cervical Neoplasms / diagnosis


29. Ma CJ, Yang SF, Huang CC, Chai CY, Cheng KI, Tsai EM, Wang JY: Malignant mixed müllerian tumor of primary mesenteric origin associated with a synchronous ovarian cancer: case report and literature review. Eur J Gynaecol Oncol; 2008;29(3):289-93
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant mixed müllerian tumor of primary mesenteric origin associated with a synchronous ovarian cancer: case report and literature review.
  • We report a patient with MMMT primarily in the mesentery with synchronous ovarian cancer.
  • Furthermore, among the cases reviewed, MMMTs tend to be associated with synchronous or metachronous colonic cancer or gynecologic tumors originating from the müllerian duct, including ovarian tumors, fallopian tube cancer, endometrial cancer, cervical cancer, and serous carcinoma of the peritoneum (14 out of 43 patients; 32.6%).
  • The prognosis of MMMT is catastrophic and the treatment is based on the experience of those of uterine sarcomas, which is composed of operation, radiotherapy and chemotherapy.
  • [MeSH-major] Adenocarcinoma / surgery. Mesentery / pathology. Mixed Tumor, Mullerian / pathology. Neoplasm Recurrence, Local / therapy. Ovarian Neoplasms / pathology
  • [MeSH-minor] Chemotherapy, Adjuvant. Fallopian Tube Neoplasms / drug therapy. Fallopian Tube Neoplasms / pathology. Fallopian Tube Neoplasms / surgery. Female. Humans. Middle Aged. Neoplasms, Multiple Primary / pathology. Neoplasms, Multiple Primary / surgery. Postmenopause


30. Huang KH, Chung SD, Huang SY, Chueh SC, Chen CA, Chen J: Coexistence of ovarian cancer and renal cell carcinoma. J Formos Med Assoc; 2007 Mar;106(3 Suppl):S15-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Coexistence of ovarian cancer and renal cell carcinoma.
  • Coexistence of ovarian cancer and renal cell carcinoma (RCC) is extremely rare.
  • Computed tomography scan showed a right cystic adnexal mass measuring 10 x 10 cm, and another tumor measuring 3 x 2 cm at the right kidney.
  • Pathologic examination revealed right ovarian clear-cell carcinoma with peritoneal, omental, and fallopian tube metastasis, and conventional clear-cell renal carcinoma.
  • Although chemotherapy was given, the patient died of disseminated ovarian cancer metastasis 20 months after operation.
  • In conclusion, coexistence of RCC and ovarian cancer is rare and the pathogenesis remains to be clarified.


31. Rose PG, Smrekar M, Haba P, Fusco N, Rodriguez M: A phase I study of oral topotecan and pegylated liposomal doxorubicin (doxil) in platinum-resistant ovarian and peritoneal cancer. Am J Clin Oncol; 2008 Oct;31(5):476-80
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I study of oral topotecan and pegylated liposomal doxorubicin (doxil) in platinum-resistant ovarian and peritoneal cancer.
  • OBJECTIVES: The feasibility, safety, and preliminary efficacy of a second-line combination therapy for oral topotecan and pegylated liposomal doxorubicin in patients with platinum-resistant or refractory epithelial ovarian, peritoneal, or tubal carcinoma were investigated in this phase I trial.
  • RESULTS: Twenty-two patients received a total of 61 courses of therapy.
  • The maximum tolerated dose of combination therapy was 1.53 mg/m(2) of topotecan on days 1 through 5 and 40 mg/m(2) of pegylated liposomal doxorubicin on day 1 of a 28-day cycle.
  • Only 5 patients completed >4 cycles of therapy.
  • However, the overall response rates after monotherapy in patients with platinum-resistant ovarian cancer are comparable to or higher than those observed in this phase I study of combination therapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Drug Resistance, Neoplasm. Organoplatinum Compounds / adverse effects. Ovarian Neoplasms / drug therapy. Peritoneal Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma, Clear Cell / drug therapy. Adenocarcinoma, Clear Cell / secondary. Administration, Oral. Adult. Aged. Aged, 80 and over. Carcinoma, Endometrioid / drug therapy. Carcinoma, Endometrioid / secondary. Cystadenocarcinoma, Serous / drug therapy. Cystadenocarcinoma, Serous / secondary. Doxorubicin / administration & dosage. Doxorubicin / analogs & derivatives. Fallopian Tube Neoplasms / drug therapy. Fallopian Tube Neoplasms / secondary. Feasibility Studies. Female. Humans. Maximum Tolerated Dose. Middle Aged. Polyethylene Glycols / administration & dosage. Prognosis. Survival Rate. Topotecan / administration & dosage

  • Genetic Alliance. consumer health - Oral cancer.
  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Topotecan .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18838885.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 0 / liposomal doxorubicin; 30IQX730WE / Polyethylene Glycols; 7M7YKX2N15 / Topotecan; 80168379AG / Doxorubicin
  •  go-up   go-down


32. Rose PG, Rodriguez M, Walker J, Greer B, Fusco N, McGuire W: A phase I trial of prolonged oral etoposide and liposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma: a gynecologic oncology group study. Gynecol Oncol; 2002 Apr;85(1):136-9
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: In an effort to explore second-line therapy in ovarian, peritoneal, and tubal carcinoma, a phase I trial combining prolonged oral etoposide and liposomal doxorubicin was conducted by the Gynecologic Oncology Group.
  • Dose-limiting toxicity was defined as neutropenic sepsis, grade 4 thrombocytopenia, absolute neutrophil count <1000/microl or platelets <50,000 during treatment with etoposide, or > or =grade 3 mucositis/stomatitis, palmar-plantar erythrodyesthesia, or rash.
  • CONCLUSION: The regimen of oral etoposide at 50 mg/m(2)/day for 12 days in combination with liposomal doxorubicin at a dose of 20 mg/m(2) is tolerable without supportive therapy.
  • While this dose of oral etoposide has demonstrated activity as a single agent in ovarian cancer, liposomal doxorubicin has only been effective in ovarian cancer at higher doses.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Fallopian Tube Neoplasms / drug therapy. Ovarian Neoplasms / drug therapy. Peritoneal Neoplasms / drug therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Drug Administration Schedule. Etoposide / administration & dosage. Etoposide / adverse effects. Female. Humans. Liposomes. Middle Aged

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11925133.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA27469; United States / NCI NIH HHS / CA / CA37517
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Liposomes; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin
  •  go-up   go-down


33. Penson RT, Campos SM, Seiden MV, Krasner C, Fuller AF Jr, Goodman A, Roche M, Willman A, Muzikansky A, Matulonis UA, Gynecologic Oncology Research Program at Dana Farber/Partners CancerCare: A phase II study of fixed dose rate gemcitabine in patients with relapsed müllerian tumors. Int J Gynecol Cancer; 2005 Nov-Dec;15(6):1035-41
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gemcitabine (2',2'-difluorodeoxycytidine) is a novel purine analog with clinical activity against ovarian cancer.
  • Women with ovarian, fallopian tube, or primary peritoneal carcinoma and documented recurrent disease were eligible for the study.
  • Patients could not have received more than four prior lines of chemotherapy and had to have measurable or evaluable disease.
  • Eighty-eight cycles of therapy were delivered (median 2 [range, 1-6]).
  • In 28 patients, there was only one partial response (4%, 95% CI 0-18%) and median time to progression was 1.7 (interquartile range, 1.2-3.9) months.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / administration & dosage. Deoxycytidine / analogs & derivatives. Genital Neoplasms, Female / drug therapy. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Adult. Aged. Carboplatin / therapeutic use. Disease Progression. Dose-Response Relationship, Drug. Drug Resistance, Neoplasm. Female. Humans. Middle Aged. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16343179.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; BG3F62OND5 / Carboplatin
  •  go-up   go-down






Advertisement